Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Burns - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2017, provides an overview of the Burns (Dermatology) pipeline landscape. A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 2, 11, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology). - The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Burns - Overview Burns - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Burns - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Burns - Companies Involved in Therapeutics Development AlgiPharma AS Alliance Pharma Plc Amarantus Bioscience Holdings Inc American Gene Technologies International Inc Biogenomics Ltd CytoTools AG Destiny Pharma Ltd GangaGen Inc Lakewood-Amedex Inc Madam Therapeutics BV Mallinckrodt Plc MediWound Ltd Mitochon Pharmaceuticals Inc Phosphagenics Ltd Se-cure Pharmaceuticals Ltd USV Pvt Ltd Burns - Drug Profiles (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile Product Description Mechanism Of Action R&D Progress A-3APO - Drug Profile Product Description Mechanism Of Action R&D Progress AG-110 - Drug Profile Product Description Mechanism Of Action R&D Progress albumin (recombinant) - Drug Profile Product Description Mechanism Of Action R&D Progress ALLO-ASC - Drug Profile Product Description Mechanism Of Action R&D Progress AyuV-25 - Drug Profile Product Description Mechanism Of Action R&D Progress Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress bromelains - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Dermatology and Immunology - Drug Profile Product Description Mechanism Of Action R&D Progress epidermal growth factor biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Burns - Drug Profile Product Description Mechanism Of Action R&D Progress IMSP-001 - Drug Profile Product Description Mechanism Of Action R&D Progress lidocaine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile Product Description Mechanism Of Action R&D Progress MP-101 - Drug Profile Product Description Mechanism Of Action R&D Progress Neu-2000 - Drug Profile Product Description Mechanism Of Action R&D Progress Nu-2 - Drug Profile Product Description Mechanism Of Action R&D Progress Oligomer G for Burn Wounds - Drug Profile Product Description Mechanism Of Action R&D Progress P-12 - Drug Profile Product Description Mechanism Of Action R&D Progress P-128 - Drug Profile Product Description Mechanism Of Action R&D Progress P-148 - Drug Profile Product Description Mechanism Of Action R&D Progress PEP-04 - Drug Profile Product Description Mechanism Of Action R&D Progress Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress SC-106 - Drug Profile Product Description Mechanism Of Action R&D Progress silver sulfadiazine - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Burns - Drug Profile Product Description Mechanism Of Action R&D Progress sodium hypochlorite - Drug Profile Product Description Mechanism Of Action R&D Progress Vanadis-02 - Drug Profile Product Description Mechanism Of Action R&D Progress XF-70 - Drug Profile Product Description Mechanism Of Action R&D Progress Burns - Dormant Projects Burns - Discontinued Products Burns - Product Development Milestones Featured News & Press Releases Mar 03, 2017: Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid in Burn Management Published in BioMed Research International Feb 09, 2017: Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area Feb 06, 2017: MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four Aug 24, 2016: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2016 Aug 08, 2016: Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns Jun 07, 2016: MediWound's NexoBrid Receives Reimbursement in Italy May 19, 2016: MediWound's NexoBrid Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting May 02, 2016: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized Feb 22, 2016: Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS) Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania Oct 31, 2015: Anterogen: Phase II IND Approval for "ALLO-ASC-BI" Oct 26, 2015: Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Burns, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Burns - Pipeline by AlgiPharma AS, H1 2017 Burns - Pipeline by Alliance Pharma Plc, H1 2017 Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Burns - Pipeline by American Gene Technologies International Inc, H1 2017 Burns - Pipeline by Biogenomics Ltd, H1 2017 Burns - Pipeline by CytoTools AG, H1 2017 Burns - Pipeline by Destiny Pharma Ltd, H1 2017 Burns - Pipeline by GangaGen Inc, H1 2017 Burns - Pipeline by Lakewood-Amedex Inc, H1 2017 Burns - Pipeline by Madam Therapeutics BV, H1 2017 Burns - Pipeline by Mallinckrodt Plc, H1 2017 Burns - Pipeline by MediWound Ltd, H1 2017 Burns - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017 Burns - Pipeline by Phosphagenics Ltd, H1 2017 Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2017 Burns - Pipeline by USV Pvt Ltd, H1 2017 Burns - Dormant Projects, H1 2017 Burns - Dormant Projects, H1 2017 (Contd..1), H1 2017 Burns - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
